KEAP1 and cystic fibrosis: C. anthelminticum FO and its fraction (i.e HF, CF, and EF) administered to treatment groups showed a decrease in the expression of Nrf2, Keap1, and HO-1 as compared to the diabetic group (p < 0.05).